Angiogenesis and its role in colorectal tumor and metastasis formation

被引:43
作者
Ellis, LM
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA
关键词
D O I
10.1053/j.seminoncol.2004.11.028
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Advances in our comprehension of cancer biology and metastasis formation have led to the development of new therapeutic approaches that target tumor biology. The survival and establishment of metastatic lesions depend on a shift in the normal balance of key regulatory factors in favor of angiogenesis. Although a number of these factors have been identified, the most potent regulator of angiogenesis is vascular endothelial growth factor (VEGF). In phase I trials, targeting VEGF with single-agent therapy did not produce clinical benefit for patients, despite promise in preclinical trials. However, the recent data showing that anti-VEGF therapy can enhance the effects of chemotherapy demonstrate the utility in targeting angiogenic factors as a component of antineoplastic regimens. A better understanding of the functions of VEGF allows the development of new hypotheses with regard to its mechanism of action. This article will highlight what is known about colorectal cancer angiogenesis, and will discuss how therapy targeting VEGF may enhance the effects of chemotherapy (and radiation therapy). © 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:3 / 9
页数:7
相关论文
共 86 条
[71]  
Stoeltzing O, 2003, CANCER RES, V63, P3370
[72]   Inhibition of integrin α5β1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice [J].
Stoeltzing, O ;
Liu, WB ;
Reinmuth, N ;
Fan, F ;
Parry, GC ;
Parikh, AA ;
McCarty, MF ;
Bucana, CD ;
Mazar, AP ;
Ellis, LM .
INTERNATIONAL JOURNAL OF CANCER, 2003, 104 (04) :496-503
[73]   Suppression of p53 activity and p21(WAF1/CIP1) expression by vascular cell integrin alpha v beta 3 during angiogenesis [J].
Stromblad, S ;
Becker, JC ;
Yebra, M ;
Brooks, PC ;
Cheresh, DA .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (02) :426-433
[74]  
TAKAHASHI Y, 1995, CANCER RES, V55, P3964
[75]  
Takahashi Y, 1997, ARCH SURG-CHICAGO, V132, P541
[76]  
Takebayashi Y, 1996, CANCER, V78, P226, DOI 10.1002/(SICI)1097-0142(19960715)78:2<226::AID-CNCR6>3.3.CO
[77]  
2-G
[78]   Angiopoietin-1 protects the adult vasculature against plasma leakage [J].
Thurston, G ;
Rudge, JS ;
Ioffe, E ;
Zhou, H ;
Ross, L ;
Croll, SD ;
Glazer, N ;
Holash, J ;
McDonald, DM ;
Yancopoulos, GD .
NATURE MEDICINE, 2000, 6 (04) :460-463
[79]   Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis [J].
Thurston, G .
CELL AND TISSUE RESEARCH, 2003, 314 (01) :61-68
[80]   Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors [J].
Tong, RT ;
Boucher, Y ;
Kozin, SV ;
Winkler, F ;
Hicklin, DJ ;
Jain, RK .
CANCER RESEARCH, 2004, 64 (11) :3731-3736